Ulcer

Kangpu Biopharmaceuticals to Present Preclinical Efficacy Data of KPG-818 in Crohn's Disease at the 19th Congress of ECCO (IND Application for Phase II in Progress)

Retrieved on: 
Tuesday, February 20, 2024
Therapy, Crohn's disease, Inflammation, FDA, Animal, Poster, Congress, Ulcer, IND, ECCO, Cancer, Pharmaceutical industry

Crohn's disease is a chronic and difficult-to-treat autoimmune disorder.

Key Points: 
  • Crohn's disease is a chronic and difficult-to-treat autoimmune disorder.
  • The current available therapeutic options for this condition are very limited, and there remain significant unmet medical needs.
  • In preclinical studies, KPG-818 demonstrated potent therapeutic efficacy in mouse model of Crohn's disease.
  • Based on the recent Pre-IND meeting with the FDA, Kangpu Biopharmaceuticals will submit IND application for Phase II clinical trials of KPG-818 for Crohn's disease in the United States.

The Inner Circle Acknowledges, Howard Siegel, MD as a Pinnacle Lifetime Member

Retrieved on: 
Monday, February 19, 2024
Dedication, Psychology, Inner circle, Multimedia, Chicago Medical School, Medical degree, Associate, Mount Sinai Beth Israel, University, Hepatitis, Society, Gastrointestinal Endoscopy, Specialization, Mentorship, Memory, Internal medicine, Health, Patient, Diagnosis, Gastroenterology, Ulcer, Esophagus, Veterans Health Administration, P.C, Nursing

NEW YORK, Feb. 19, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Howard Siegel, MD is acknowledged as a Pinnacle Lifetime Member for his contributions as a Gastroenterologist with 57 Years of Dedication and Expertise.

Key Points: 
  • NEW YORK, Feb. 19, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Howard Siegel, MD is acknowledged as a Pinnacle Lifetime Member for his contributions as a Gastroenterologist with 57 Years of Dedication and Expertise.
  • His unwavering commitment to patient care has made him a respected figure in the field of gastroenterology.
  • Dr. Siegel's practice, Manhattan Internal Medicine Associates, P.C., is renowned for providing advanced and personalized gastroenterological care.
  • In memory of his esteemed mentors, Dr. Siegel pays tribute to the invaluable guidance and support received from Dr. Edward King, MD, and Dr. David.

EQS-News: Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and sponsorship of scientific symposium at the 19th Congress of European Crohn’s and Colitis Organization (ECCO)

Retrieved on: 
Tuesday, February 13, 2024
Therapy, Ulcerative colitis, European, A12, UC, Abstract, Patient, IBD, Symposium, Congress, Symposium (Plato), Ulcer, Euronext Paris, ECCO, Pharmaceutical industry

“We are delighted that all four submitted abstracts have been accepted for presentations at ECCO.

Key Points: 
  • “We are delighted that all four submitted abstracts have been accepted for presentations at ECCO.
  • We look forward to scientific exchange with the IBD community at ECCO,” said Sheldon Sloan, M.D., M. Bioethics, Chief Medical Officer of Abivax.
  • (Germany), on February 23, 2024, at 7:15-8:15 a.m. CET in room A12.
  • The Symposium will be broadcasted live and is accessible publicly here .

Studies Show African Americans are 60% More Likely to Be Diagnosed with Diabetes and 3x as Likely to Lose a Limb Due to Amputation

Retrieved on: 
Tuesday, February 6, 2024
African Americans, Amputation, Savyon, Inula, Research, Wound, Diabetes, Walmart, Ulcer, Environment, FDA, Abrasion, American Diabetes Association, Entrepreneurship, Disease, Quality of life, Pharmaceutical industry

MIAMI, Feb. 6, 2024 /PRNewswire/ -- Lavior Pharma is on a mission to address health disparities affecting African Americans, who are 60% more likely to be diagnosed with diabetes and three times more likely to undergo amputation as a result. As the only company with a comprehensive over-the-counter diabetic wound and skin care product line, Lavior is committed to offering safe, effective, affordable and accessible solutions to provide life-saving treatment at home.

Key Points: 
  • MIAMI, Feb. 6, 2024 /PRNewswire/ -- Lavior Pharma is on a mission to address health disparities affecting African Americans, who are 60% more likely to be diagnosed with diabetes and three times more likely to undergo amputation as a result.
  • Lavior products are available at Walmart and on Walmart.com for less than $20 for a 30-day supply.
  • Lavior products are available at Walmart and on Walmart.com for less than $20 for a 30-day supply.
  • It has led to an effective suite of products that are designed to heal wounds, not just manage them.

Microbix Unveils Test Control for Gastric Ulcer Disease Pathogen

Retrieved on: 
Tuesday, February 6, 2024
Poster, Product management, OTCQX, QAP, Tropical ulcer, Bacteria, MDX, Ulcer, Diagnosis, Temperature, EQA, Laboratory, TSX, Nobel Prize, QMS, Stomach, Infection, RUO, Accreditation, Helicobacter pylori, Medical device

H. pylori infection was discovered to be the cause of stomach (gastric) ulcers in the 1980’s, in what became a Nobel Prize winning health discovery.

Key Points: 
  • H. pylori infection was discovered to be the cause of stomach (gastric) ulcers in the 1980’s, in what became a Nobel Prize winning health discovery.
  • It is difficult to culture this pathogen, leading to the use of MDx methods for rapid diagnosis.
  • It is sponsored by Labquality Oy, a well-established Scandinavian clinical-lab proficiency and accreditation authority that is a Microbix customer and collaborator (https://www.labquality.com).
  • These H. pylori QAPs are now being made available on a research-use-only (RUO) basis from Microbix as part of its PROCEEDx®FLOQ® catalogue of products.

Urology Care Foundation Spreads Awareness for National Cancer Prevention Month

Retrieved on: 
Wednesday, January 31, 2024
Education, Ache, Penile cancer, Urethral cancer, Urination, Kidney cancer, Bleeding, Fluid mechanics, Testicular cancer, Heredity, Urethra, Radiation, Back pain, Infection, Bladder cancer, Abdomen, Foreskin, Weight loss, FACS, Fever, Groin, Risk factor, Diet, AUA, Blog, Cancer, HPV, Combustion, Woman, Urethral caruncle, Growth, Papillomaviridae, Prostate cancer, Low back pain, Penis, Urethral diverticulum, Rib, Death, Skin, Blood, Disease, AIDS, Risk, Ejaculation, Smoking, Workplace, UTI, American Urological Association, Male, Scrotum, Pain, Tenderness, MBA, Somatic symptom disorder, Urine, Smoker, GCNIS, Ulcer, Birth control

BALTIMORE, Jan. 31, 2024 (GLOBE NEWSWIRE) -- February is National Cancer Prevention Month, and the Urology Care Foundation, the official foundation of the American Urological Association (AUA), wants to spread awareness and information on the six main urologic cancers.

Key Points: 
  • BALTIMORE, Jan. 31, 2024 (GLOBE NEWSWIRE) -- February is National Cancer Prevention Month, and the Urology Care Foundation, the official foundation of the American Urological Association (AUA), wants to spread awareness and information on the six main urologic cancers.
  • However, there are other urologic cancers that involve the bladder, kidneys and testicles,” said Urology Care Foundation Board of Directors member Brian McNeil, MD, MBA, FACS.
  • The Urology Care Foundation believes the first part of prevention is education.
  • Below are the six main urologic cancers and important resources for each:
    Bladder Cancer is the second most common type of urologic cancer.

RION Announces Initiation of Phase 2A Clinical Study for Purified Exosome Product™ (PEP™) in Diabetic Foot Ulcers

Retrieved on: 
Tuesday, January 30, 2024
Health, Diabetes, Clinical Trials, Research, Science, Biotechnology, Multimedia, DFU, Amputation, Regenerative medicine, Mayo Clinic, Diabetic foot, Patient, Safety, Exosome, Biologics license application, Ulcer, BLA, Pharmaceutical industry

RION, a clinical-stage regenerative medicine company, at the forefront of the exosome therapeutic revolution, has officially commenced a Phase 2A study aimed at assessing the efficacy and safety of its exclusive exosome regenerative therapeutic, known as Purified Exosome Product™ (PEP™), for the management of Diabetic Foot Ulcers (DFU).

Key Points: 
  • RION, a clinical-stage regenerative medicine company, at the forefront of the exosome therapeutic revolution, has officially commenced a Phase 2A study aimed at assessing the efficacy and safety of its exclusive exosome regenerative therapeutic, known as Purified Exosome Product™ (PEP™), for the management of Diabetic Foot Ulcers (DFU).
  • (Photo: Business Wire)
    Diabetic Foot Ulcers affect approximately 18.6 million people worldwide each year1 and are associated with increasing rates of amputation and death​​.
  • Building on the success of the Phase 1B study conducted at Mayo Clinic, RION's Phase 2A trial represents a significant step forward in the development of a regenerative biologic for Diabetic Foot Ulcers.
  • Not only will this study address a critical unmet need in chronic wound care, but it’s a pivotal moment for RION.

Recce Pharmaceuticals Reports Positive Phase I/II Trial Results of RECCE® 327 for the Treatment of Diabetic Foot Infections

Retrieved on: 
Tuesday, January 23, 2024
Diabetes, Obesity, Type, Patient, Diabetic neuropathy, Meta-analysis, Hypertension, Infection, Male, Foot, History, DFI, Dyslipidemia, Staphylococcus aureus, Recurrence, Amputation, Ulcer, Prevalence, Staphylococcus, Presser foot, Blood, Pharmaceutical industry

The patient was on systemic therapy and was required to stop treatment to meet the trial protocol of R327, requiring solely topical application.

Key Points: 
  • The patient was on systemic therapy and was required to stop treatment to meet the trial protocol of R327, requiring solely topical application.
  • On day 15 (midpoint), post-R327 treatment, the initial redness of the wound and swelling of the foot had minimized and reduced in size.
  • Due to patient comorbidities and the complexity of the wound, the patient was returned to systemic therapy, resulting in disqualification from the trial.
  • After three doses of R327 treatment (midpoint – day 7), the infection was significantly reduced, with the wound drying and rapidly improving.

Heron Therapeutics Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures

Retrieved on: 
Wednesday, January 24, 2024
System, Death, Allergy, Heron, Patient, Vitamin, Naproxen, Elective surgery, SAN, Health, Partnership, Foot, Gastrointestinal bleeding, Ibuprofen, Vomiting, Anemia, Ankle, Stroke, Heart failure, Medicine, Nonsteroidal anti-inflammatory drug, Patient satisfaction, Cartilage, Risk, Meloxicam, Pain, VAN, Cross-link, Food, Constipation, Pregnancy, NDA, Anesthetic, Aspirin, Tears, FDA, Ulcer, Liver, Boxed warning, New Drug Application, Headache, Bupivacaine, Human, Blood, Pharmaceutical industry

SAN DIEGO, Jan. 23, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that the U.S. Food and Drug Administration (the "FDA") has approved its supplemental New Drug Application ("NDA") for ZYNRELEF® (bupivacaine and meloxicam) extended-release solution to expand the indication for soft tissue and orthopedic surgical procedures including foot and ankle, and other procedures in which direct exposure to articular cartilage is avoided. ZYNRELEF was previously approved for foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures in adults.

Key Points: 
  • ZYNRELEF was previously approved for foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures in adults.
  • This expanded indication for ZYNRELEF will now cover an estimated 13 million procedures annually, an estimated increase of 86% over prior indicated procedures.
  • To obtain this labeling expansion, Heron successfully conducted studies for cesarean section, spinal surgery, augmentation mammoplasty, and total shoulder arthroplasty.
  • The most common side effects of ZYNRELEF are soft tissue procedures: vomiting and orthopedic procedures: constipation and headache.

Osteoarthritis Therapeutics Market to grow by USD 3.96 billion from 2022-2027, North America to account for 32% of market growth - Technavio

Retrieved on: 
Wednesday, January 17, 2024
Obesity, X-ray, Regenerative medicine, Osteoarthritis, Risk, Therapy, Research, MRI, Pressure, ROW, Analgesic, NSAID, Health, Pain management, FREE, Nonsteroidal anti-inflammatory drug, Disease, Pfizer, Eli Lilly, Nonsteroidal, Drug development, USD, Ulcer, Burns, Biomarker, DSM-IV codes, Inflammation, Rheumatology, Ageing, Growth, Pharmaceutical industry

NEW YORK, Jan. 16, 2024 /PRNewswire/ -- The osteoarthritis therapeutics market size is expected to grow by USD 3.96 billion from 2022 to 2027.

Key Points: 
  • NEW YORK, Jan. 16, 2024 /PRNewswire/ -- The osteoarthritis therapeutics market size is expected to grow by USD 3.96 billion from 2022 to 2027.
  • North America will contribute 32% to the growth of the global market during the forecast period.
  • Such diagnostic advancements not only aid in understanding drug effectiveness but also drive growth in the osteoarthritis therapeutics market.
  • Growth of the osteoarthritis therapeutics market across North America, Europe, Asia, and ROW
    Comprehensive analysis of factors that will challenge the growth of osteoarthritis therapeutics market vendors.